The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDci Advisors Regulatory News (DCI)

Share Price Information for Dci Advisors (DCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.75
Bid: 4.50
Ask: 5.00
Change: 0.09 (1.89%)
Spread: 0.50 (11.111%)
Open: 4.75
High: 4.86
Low: 4.75
Prev. Close: 4.75
DCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Legal Update

28 Mar 2024 09:43

RNS Number : 6934I
DCI Advisors Limited
28 March 2024
 

This announcement has been determined to contain inside information for the purposes of the UK version of the market abuse regulation (EU) No.596/2014.

 

DCI Advisors Limited

(the "Company")

 

 

Legal Update

 

28 March 2023

 

In follow up on our legal update 13 December 2023;

 

Filing of approximately ?57.0 million in civil claims in Greece

Following the filing by DCI Advisors Limited (DCI) of criminal charges in Greece on 12 December 2023, last week DCI filed civil claims against 10 individuals/companies in order to seek to recover approximately ?57.0 million in damages and the cancellation of a transaction against one company in Cyprus. DCI's investigations into potential wrongdoing are continuing.

Summary Judgement UK

On 21 March 2024 the High Court of Justice in London decided at the hearing of DCI's Application for reverse summary judgment / strike out (the 'Application') that a full trial is needed to determine the Claim issued by Dolphin Capital Partners Limited (DCP) and the Counterclaim filed by DCI involving the Amanzoe call option issued by the buyer of Amanzoe in August 2018 to DCP, who at that time was the Investment Manager of DCI.

Some observations and quotes in the Deputy Judge's judgment of interest are:

- Of the three witnesses who provided signed statements on behalf of DCP ; "Two of those three witnesses are qualified and regulated legal professionals."

- "[DCP's] three witnesses explain in their statements that the Call Option was also mentioned in that meeting without any objection on behalf of [DCI]."

- "The main problem for [DCP] in this context is that none of the documents which relate to the board meeting make mention of the Call Option or its effect. "

- "[DCI's] counsel also conducted a withering critique of the witness evidence itself, pointing out its mutually supportive terms and aspects which appear to be contradictory. I have some forensic sympathy with these criticisms. The witnesses can expect to face some testing cross-examination at trial, should the matter proceed that far."

- "There is more than a fanciful prospect of [DCP's] version being accepted at trial, however slender that may seem when the three attendees' witness evidence is considered in its own terms and compared with the contemporary communications and records of events."

- "The trial judge may yet conclude that their evidence is concocted. Any such finding would have serious personal and professional consequences for each of them, as they are no doubt already aware. This is all a matter for the trial judge."

Whilst DCI's Application for reverse summary judgment / strike out was dismissed, the Deputy Judge decided that DCI is not at this stage required to pay DCP's costs of the Application, and instead reserved the costs of the Application to the trial judge. That costs order was made in order to mitigate the injustice that would be caused if DCI paid DCP's costs and it was subsequently found at trial that DCP's witness evidence submitted in support of its opposition to the Application had been concocted. 

A copy of the judgment can be found at:

https://www.bailii.org/ew/cases/EWHC/Comm/2024/678.html

BVI Update

Regarding the statutory demand issued by DCP's close business partner Zoniro Ltd [as previously announced on 13 December 2023], the hearing scheduled to be held in the BVI Court is postponed until May 2024 when the matter will be determined. Until that time, we do not expect any material developments in those proceedings.

Enquiries

DCI Advisors Ltd

Nicolai Huls / Nick Paris, Managing Directors

 

nickparis@btinternet.com

+44 (0) 7738 470550

Cavendish Capital Markets (Nominated Adviser & Broker)

James King / Jonny Franklin?Adams / Edward Whiley / Oscar Valeur?Adu (Corporate Finance)

Pauline Tribe (Sales)

 

 

+44 (0) 20 7220 0500

FIM Capital Limited (Administrator)

Lesley Lennon / Grainne Devlin (Corporate Governance)

llennon@fim.co.im / gdevlin@fim.co.im

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDPPUBWWUPCUBR
Date   Source Headline
16th Apr 202412:38 pmRNSShareholder Loan & Related Party Transaction
15th Apr 20242:26 pmRNSShareholder Update
2nd Apr 20243:33 pmRNSUpdate on legal actions
28th Mar 20249:43 amRNSLegal Update
14th Mar 20242:57 pmRNSFurther Shareholder Loan and RPT
27th Feb 20242:17 pmRNSHolding(s) in Company
23rd Feb 20245:00 pmRNSHolding(s) in Company
9th Feb 20245:07 pmRNSFurther Shareholder Loan
9th Feb 20243:39 pmRNSHolding(s) in Company
27th Dec 20232:23 pmRNSGovernment Grant to the Kilada Project
15th Dec 20239:36 amRNSResult of AGM
13th Dec 20238:53 amRNSShareholder Loan
13th Dec 20238:46 amRNSUpdate on legal actions
1st Dec 20233:44 pmRNSHolding(s) in Company
22nd Nov 202312:32 pmRNSAGM Timing
21st Nov 202311:30 amRNSNotice of AGM
16th Nov 20233:31 pmRNSShareholder Loan
6th Oct 20232:17 pmRNSShareholder Loan
29th Sep 20237:00 amRNSHalf-year Report
14th Sep 202312:32 pmRNSShareholder Loans and a Related Party Transaction
7th Sep 20234:17 pmRNSHolding(s) in Company
30th Aug 202310:22 amRNSDirector/PDMR Shareholding
29th Aug 202310:07 amRNSDirector/PDMR Shareholding
21st Aug 202311:46 amRNSHolding(s) in Company
8th Aug 20239:23 amRNSDirector/PDMR Shareholding
3rd Aug 20234:35 pmRNSDirector/PDMR Shareholding
1st Aug 20234:33 pmRNSNotification of Transaction of a PCA
27th Jul 20233:14 pmRNSDirector/PDMR Shareholding
30th Jun 20231:25 pmRNSAnnual Financial Report
29th Jun 20234:50 pmRNSShareholder Loans
7th Jun 20237:00 amRNSChange of Name
26th May 20232:19 pmRNSShareholder Loans
26th May 20239:41 amRNSKilada Funding
3rd May 20234:24 pmRNSHolding(s) in Company
28th Apr 20239:41 amRNSShareholder Loans
27th Apr 20232:45 pmRNSHolding(s) in Company
19th Apr 20237:00 amRNSShareholder Loans and Related Party Transaction
18th Apr 202310:30 amRNSShareholder Update
13th Apr 20234:21 pmRNSHolding(s) in Company
13th Apr 20233:58 pmRNSHolding(s) in Company
11th Apr 20234:36 pmRNSHolding(s) in Company
11th Apr 20233:12 pmRNSFiling of Claim Form
6th Apr 20234:50 pmRNSHolding(s) in Company
5th Apr 20234:39 pmRNSNew website now live
31st Mar 20236:13 pmRNSCompany Website
20th Mar 20237:00 amRNSTermination of Inv. Manager & Removal of Director
17th Feb 20233:48 pmRNSHolding(s) in Company
13th Feb 20237:00 amRNSDirectorate Change
23rd Dec 20229:07 amRNSCompletion of disposal of interest in OOKI
31st Oct 202210:24 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.